Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹607.00
₹14.40(2.38%)
At close: 4:00 PM EDT
₹607.00
₹14.40(2.38%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹868.75
Previous CloseN/A
Volume305.42K
Average Volume (3M)38.83K
Market Cap
₹168.62B
Enterprise Value₹74.34K
Total Cash (Recent Filing)₹451.80M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)56.6
Beta0.77
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.06%
Share Statistics
EPS (TTM)15.20
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.63
Price to Sales (P/S)4.43
P/FCF Ratio-90.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.27
Revenue Forecast (FY)₹18.29B
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings RecoveryThe recovery from FY2023 losses and faster FY2026 revenue growth indicate improved demand, execution and operating traction. Sustained growth would strengthen the company’s ability to fund development, commercialization and manufacturing expansion.
Improved Operating ProfitabilityStrong EBIT and EBITDA margins provide a healthier base for competing in complex APIs and finished formulations. If maintained, the improved margin structure can support reinvestment, resilience and better earnings quality over the medium term.
Lower Leverage And Asset GrowthConservative leverage reduces balance-sheet risk and preserves borrowing capacity for production, development and regulatory investments. Growing equity and assets also suggest the company has a stronger financial platform to support future operations.
Bears Say
Persistent Negative Free Cash FlowPersistent negative free cash flow means reported profits are not translating into surplus cash after investment needs. This can increase reliance on financing or working-capital management and may constrain the pace of sustainable growth.
Earnings And Margin VolatilityLarge changes in profitability and the FY2026 gross-margin decline indicate that product mix, pricing or costs may remain unstable. This makes future earnings less predictable and could limit the durability of the recent margin recovery.
Inconsistent Returns On CapitalWeak or negative historical ROE shows that the enlarged capital base has not consistently produced strong shareholder returns. Until the rebound is demonstrated over multiple periods, capital efficiency remains an important structural weakness.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹868.75 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹168.62B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is Nov 06, 2026 which is in 71 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Aug 05, 2026. The company reported ₹5.18 earnings per share for the quarter, beating the consensus estimate of ₹4 by ₹1.18.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of 0.06%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹5.18 in its last earnings report, beating expectations of ₹4. Following the earnings report the stock price went up 11.251%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Jubilant Pharmova Limited
―
Strides Pharma Science Ltd
―